Herbert Andres

This inventor holds 23 USPTO granted patents and 22 published patent applications, plus 6 CIPO patents and 12 EPO patents, primarily in Biomarker Detection. Top assignees: Roche Diagnostics Operations, Inc., Hoffmann-La Roche Inc., Roche Diagnostics Gmbh. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Herbert Andres. Retrieved from https://idiyas.com/inventor/herbert-andres

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 22)

% Patents Active = 65.2

CIPO Patents = 6 (Patent Applications = 7)

EPO Patents = 12 (Patent Applications = 25)

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Penaberg, DE (2021)
Penzberg, DE (2005 - 2024)

Company Filing History:

17 out of 1,700

Roche Diagnostics Operations, Inc.

patents

3 out of 5,027

Hoffmann-La Roche Inc.

patents

2 out of 489

Roche Diagnostics Gmbh

patents

4. 1 out of 834,601

Other

patents

Years Active: 2005-2025

Loading Chart...

Areas of Expertise:

Electrochemiluminescence

Anti-p53 Antibodies

Fusion Polypeptide

Angiopoietin-2

Rheumatoid Arthritis

Lung Cancer

Colorectal Cancer

Breast Cancer

Protein Complexes

Chaperones

Cancer Markers

Insulin-like Growth Factor

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12372474 - Branched-chain amines in electrochemiluminescence detection (2025-07-29),

2. 12306185 - Detection of anti-p53 antibodies (2025-05-20),

3. 11971407 - Detection of anti-p53 antibodies (2024-04-30),

4. 11644472 - Circulating Angiopoietin-2 (Ang-2) for the prediction of recurrence of atrial fibrillation (2023-05-09),

5. 11125695 - Branched-chain amines in electrochemiluminescence detection (2021-09-21),

6. 10647765 - Amino acid sequence presenting fusion polypeptide and its use (2020-05-12),

7. 10301383 - Antibody specifically binding to insulin-like growth factor-1 (2019-05-28),

8. 10175241 - ASC as a marker for lung cancer (2019-01-08),

9. 10094826 - Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD (2018-10-09),

10. 9938340 - Amino acid sequence presenting fusion polypeptide and its use (2018-04-10),

11. 9273144 - Antibody specifically binding to insulin-like growth factor-1 (2016-03-01),

12. 9266962 - Amino acid sequence presenting fusion polypeptide and its use (2016-02-23),

13. 9116156 - ASC as a marker for chronic obstructive pulmonary disease (COPD) (2015-08-25),

14. 8951738 - CYBP as a marker for lung cancer (2015-02-10),

15. 8426167 - Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides (2013-04-23),

Certainly! Here is the article about inventor Herbert Andres:

Title: Unveiling the Innovations of Herbert Andres: A Trailblazer in Medical Diagnostics

Introduction:

Herbert Andres, a prolific inventor hailing from Penzberg, Germany, has left an indelible mark in the field of medical diagnostics. With an impressive portfolio of 20 patents to his name, Andres has spearheaded groundbreaking advancements in predictive healthcare technologies.

Latest Patents:

Among his recent patents is the groundbreaking method for predicting the risk of recurrence of Atrial Fibrillation, a common heart rhythm disorder. This innovative technique revolves around measuring the biomarker Angiopoietin-2 (Ang-2) in a patient's sample to assess the likelihood of atrial fibrillation recurrence. Additionally, Andres has pioneered the utilization of branched-chain amines in electrochemiluminescence detection, revolutionizing the detection of analytes in biological samples.

Career Highlights:

Andres has graced the corridors of esteemed organizations such as Roche Diagnostics Operations, Inc. and Hoffmann-La Roche Inc., where his inventive spirit thrived. His tenure at these renowned companies has been marked by a relentless pursuit of excellence and a commitment to driving transformative changes in the realm of medical diagnostics.

Collaborations:

Throughout his illustrious career, Herbert Andres has collaborated closely with notable professionals in the field, including the likes of Christian Scholz and Johann Karl. Together, they have synergized their expertise to push the boundaries of innovation and bring cutting-edge solutions to the forefront of medical science.

Conclusion:

In conclusion, Herbert Andres stands as a beacon of ingenuity in the realm of medical diagnostics, with his remarkable inventions reshaping the landscape of predictive healthcare technologies. His unwavering dedication to innovation and his collaborative spirit underscore the transformative impact he has had on the industry. Herbert Andres continues to inspire future generations of inventors to push the boundaries of possibility and usher in a new era of medical innovation.

Profile summary based on public USPTO records.